Discontinuation report ZERIT - CAP 40MG
Report ID | 55462 |
Drug Identification Number | 02216116 |
Brand name | ZERIT - CAP 40MG |
Common or Proper name | STAVUDINE |
Company Name | BRISTOL-MYERS SQUIBB CANADA |
Market Status | CANCELLED POST MARKET |
Active Ingredient(s) | STAVUDINE |
Strength(s) | 40MG |
Dosage form(s) | CAPSULE |
Route of administration | ORAL |
Packaging size | 1 BTL x 60 |
ATC code | J05AF |
ATC description | DIRECT ACTING ANTIVIRALS |
Reason for discontinuation | Business reasons |
Anticipated discontinuation date | 2020-03-31 |
Actual discontinuation date | 2020-03-31 |
Remaining supply date | 2020-03-31 |
Discontinuation status | Discontinued |
Discontinuation decision reversal | No |
Information on remaining supply | All strengths are being deleted. |
Company comments | |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 2344 BOUL. ALFRED-NOBEL, SUITE 300 ST-LAURENT, QUEBEC CANADA H4S 0A4 |
Company contact information | For more information please contact the Customer Service Desk at 1-800-267-0005 |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v4 | 2020-04-01 | French | Compare |
v3 | 2020-04-01 | English | Compare |
v2 | 2018-07-11 | French | Compare |
v1 | 2018-07-11 | English | Compare |
Showing 1 to 4 of 4